SynCore Biotechnology to attend at 2018 BIO Internat...
SynCore Biotechnology (SynCoreBio) is pleased to announce that it will join 2018 BIO International Convention held in Boston, MA on June 4-7, 2018. (http://c... more

SynCore Bio SB04 Dry-AMD in Phase II/III trial
SB04 is an invasive treatment for dry Age-related Macular Degeneration which is available for patient self-applied medication. SB04 has stepped into phase II... more

SynCore Biotechnology is to Attend ASCO in Chicago, ...
SB05 is a paclitaxel component combined with neutral and positive lipids. Due to the characteristics of targeting the blood supply of tumors, it is expected ... more

SynCore Biotechnology to Participate at the ARVO 201...
SynCore Biotechnology has announced the partnership with Epipole Ltd. (UK) for the Taiwanese distribution rights of fundus cameras epiCam® M and epiCam&r... more

SynCore Biotechnology to Participate at the ChinaBio...
SynCore Biotechnology announced that the company will attend the ChinaBio® Partnering Forum on April 25-26th ( more